Charles Schwab’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Charles Schwab’s Portfolio FOMX Stock Details FOMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-32,336	Closed	-$211K	–	3158
2016 Q1	$211K	Hold	32,336	–	–	﹤0.01%	2886
2015 Q4	$263K	Hold	32,336	–	–	﹤0.01%	2903
2015 Q3	$238K	Hold	32,336	–	–	﹤0.01%	2911
2015 Q2	$332K	Buy	+32,336	New	+$357K	﹤0.01%	2834

Other funds holding FOMX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Charles Schwab's FOMX Position: Q2 2016 in Review

Charles Schwab sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q2 2016, closing a stake of 32,336 shares — an estimated $211K sold.

Charles Schwab first reported a position in FOMX in Q2 2015 and held it in 4 quarters. The position peaked at $332K in Q2 2015. 56 funds tracked by Wall St. Rank hold FOMX as of Q2 2016.

Charles Schwab reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q2 2016 after selling out during the quarter.
Charles Schwab sold 32,336 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q2 2016, an estimated $211K.
Charles Schwab first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 4 quarters.
Charles Schwab's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $332K in Q2 2015.
56 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q2 2016.

Based on Charles Schwab's 13F filing for Q2 2016, filed 15 Aug 2016.